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Abstract: Dysfunctions of NO-cGMP signaling have been implicated in various neurological
disorders. We have studied the potential crosstalk of cGMP and Ca2+ signaling in cerebellar
granule neurons (CGNs) by simultaneous real-time imaging of these second messengers in living
cells. The NO donor DEA/NO evoked cGMP signals in the granule cell layer of acute cerebellar
slices from transgenic mice expressing a cGMP sensor protein. cGMP and Ca2+ dynamics were
visualized in individual CGNs in primary cultures prepared from 7-day-old cGMP sensor mice.
DEA/NO increased the intracellular cGMP concentration and augmented glutamate-induced Ca2+
transients. These effects of DEA/NO were absent in CGNs isolated from knockout mice lacking
NO-sensitive guanylyl cyclase. Furthermore, application of the cGMP analogues 8-Br-cGMP and
8-pCPT-cGMP, which activate cGMP effector proteins such as cyclic nucleotide-gated cation channels
and cGMP-dependent protein kinases (cGKs), also potentiated glutamate-induced Ca2+ transients.
Western blot analysis failed to detect cGK type I or II in our primary CGNs. The addition of
phosphodiesterase (PDE) inhibitors during cGMP imaging showed that CGNs degrade cGMP mainly
via Zaprinast-sensitive PDEs, most likely PDE5 and/or PDE10, but not via PDE1, 2, or 3. In sum, these
data delineate a cGK-independent NO-cGMP signaling cascade that increases glutamate-induced Ca2+
signaling in CGNs. This cGMP–Ca2+ crosstalk likely affects neurotransmitter-stimulated functions
of CGNs.
Keywords: cyclic GMP; calcium; nitric oxide; guanylyl cyclase; cerebellar granule cells; protein
kinase; PKG; FRET imaging; transgenic mice
1. Introduction
NO acts as an important messenger in the nervous system. It elevates the intracellular
concentration of cGMP, which activates downstream targets and ultimately leads to a variety of
neurophysiological responses [1]. The NO-cGMP pathway has been implicated in several aspects of the
central nervous system (CNS), such as cognition, anxiety, addiction, schizophrenia, and depression [2].
NO increases cGMP levels via activation of the hemeprotein NO-sensitive guanylyl cyclase (NO-GC),
which subsequently synthesizes cGMP from GTP. NO-GC is a heterodimeric enzyme thought to be
mainly localized in the cytosol. It exists in two isoforms, α1β1 and α2β1, where α1β1 is more prevalent
in most tissues, except for neural tissue where comparatively higher levels of α2β1 are found [3–5].
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cGMP synthesis is also stimulated via activation of transmembrane particulate guanylyl cyclases [6].
Activation of these enzymes occurs via peptides such as atrial natriuretic peptide (ANP) or C-type
natriuretic peptide (CNP).
cGMP exerts its physiological effects via the modulation of at least three types of downstream
effectors: cGMP-dependent protein kinases (cGKs), cyclic nucleotide-gated (CNG) cation channels, and
cGMP-regulated phosphodiesterases (PDEs). Mammals express three cGKs, membrane bound cGKII,
and cytosolic cGKI, which has two isoforms, known as cGKIα and cGKIβ [7]. Both cGKI and cGKII are
expressed in the CNS [8–10]. CNG channels have also been identified in the nervous system [11,12].
They consist of at least two types of subunits, termed α and β, and exist in at least five isoforms. CNG
channels are directly activated by cGMP and/or cAMP and provide a non-voltage dependent route
for Ca2+ entry into neurons, in addition to voltage-activated Ca2+ channels and plasma membrane
channels gated by excitatory neurotransmitters such as glutamate and acetylcholine. cGMP is degraded
by PDEs [13]. Interestingly, cGMP also regulates the activity of some cAMP-hydrolyzing PDEs, thus,
facilitating cross regulation of cAMP levels by cGMP. For example, binding of cGMP to PDE2 increases
the hydrolytic activity of the enzyme, resulting in a reduction in the cAMP concentration [14,15].
cGMP is implicated in various diseases, and multiple medications that increase the cGMP
concentration are already on the market for use in humans, such as the PDE5 inhibitor Sildenafil for
erectile dysfunction, the guanylyl cyclase C agonist Linaclotide for chronic idiopathic constipation and
irritable bowel syndrome, and the NO-GC stimulator Riociguat for certain forms of pulmonary
hypertension [16–19]. Given the druggability of the cGMP pathway, it would be informative
to further elucidate the cGMP signaling pathway in the nervous system. cGMP has important
functions in various regions of the brain including the cerebellum [2]. A NO-cGMP-cGKI pathway
regulates long-term-depression of synaptic activity in Purkinje cells and cerebellar learning [20].
Expression of components of the NO-cGMP pathway has also been reported in cerebellar granule
neurons (CGNs) [21], but the functional relevance of NO-cGMP signaling in the granule cell layer
of the cerebellum is not well understood. CGNs are glutamatergic interneurons that provide an
excitatory input to the molecular layer of the cerebellum. They constitute the largest neuronal
population in the cerebellum and entire brain and serve as a model to investigate neuronal signal
transduction [22]. CGNs have been shown to express Ca2+-permeable N-methyl-D-aspartate (NMDA)
receptors for glutamate [23,24]. These receptors are essential for neuronal survival and previous
research has reported that upon NMDA receptor stimulation, NO synthase is activated and NO is
synthesized [25,26].
To investigate the NO-cGMP pathway in CGNs, in particular potential cGMP–Ca2+ crosstalk,
we established primary cultures of CGNs from cGMP sensor mice and performed fluorescence imaging
experiments to visualize both NO-induced cGMP and glutamate-induced Ca2+ in real time. cGMP
was monitored via the fluorescence resonance energy transfer (FRET)-based cGMP indicator, cGi500,
that was inserted as a transgene into the mouse genome [27]. As illustrated in Figure 1A, cGi500 consists
of the two cGMP-binding sites of the bovine cGKI flanked by cyan fluorescent protein (CFP) and yellow
fluorescent protein (YFP) [28]. It is a ratiometric sensor and indicates an increase in cGMP via reduced
FRET. Ca2+ imaging was performed simultaneously with the ratiometric Ca2+-sensitive fluorescent dye
Fura-2. By simultaneous cGMP/Ca2+ imaging, this study has identified a NO-cGMP signaling cascade
that generates cGMP–Ca2+ crosstalk in murine CGNs that might affect neurotransmitter-dependent
functions in the cerebellum.
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DEA/NO (5 µM) during real-time imaging under continuous flow. As expected, the application of 
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(Figure 1F, green trace). The failure to detect ANP- or CNP-induced cGMP increases (Figure 1C,F) 
could have been related to technical issues, such as an inability of the cytosolic cGi500 sensor to detect 
presumably membrane-associated cGMP pools that are generated in response to natriuretic peptides. 
However, this possibility is highly unlikely, because the cytosolic cGi500 sensor has been successfully 
used to detect ANP- and CNP-induced cGMP signals in various other cell types including smooth 
muscle cells [27] and dorsal root ganglion neurons [29]. 
To confirm that our cultured cells were indeed neurons, cells were stained for the neuronal 
marker βIII-tubulin (Figure 1G). Over 95% of cells (detected by nuclear staining with Hoechst dye) 
were positive for βIII-tubulin indicating a nearly pure neuronal cell culture. The cultured cells had the 
typical morphology and small size (diameter ≈ 5–10 µm) of CGNs (Figure 1B), but we cannot formally 
exclude that our cerebellar cultures also contained a small number of Golgi and/or stellate neurons. 
Together, these data indicated that NO was able to reliably elevate cGMP in CGNs in the primary 
culture as well as in acute cerebellar slices. 
 
Figure 1. Visualization of cGMP in CGNs and acute cerebellar slices revealed a NO-induced cGMP 
response. (A) The cGi500 sensor consisted of cGMP-binding sites of the bovine cGKI (white) flanked 
by CFP (cyan) and YFP (yellow). Upon binding of cGMP (grey) a conformational change and a 
concomitant decrease in FRET efficiency occurred. Thus, upon excitation of CFP at 445 nm, light 
emission from YFP (535 nm) was reduced and emission from CFP (480 nm) was increased resulting 
in an increase of the CFP/YFP emission ratio when cGMP concentrations rise. Adapted from Reference 
[27]. (B) CGNs isolated from 7-day-old R26-CAG-cGi500(L1) mice expressed the cGi500 sensor 
Figure 1. Visualization of cGMP in CGNs and acute cerebellar slices revealed a NO-induced cGMP
response. (A) The cGi500 sensor consisted of cGMP-binding sites of the bovine cGKI (white) flanked by
CFP (cyan) and YFP (yellow). Upon binding of cGMP (grey) a conformational change and a concomitant
decrease in FRET efficiency occurred. Thus, upon excitation of CFP at 445 nm, light emission from YFP
(535 nm) was reduced and emission from CFP (480 nm) was increased resulting in an increase of the
CFP/YFP emission ratio when cGMP concentrations rise. Adapted from Reference [27]. (B) CGNs
isolated from 7-day-old R26-CAG-cGi500(L1) mice expressed the cGi500 sensor (green). The green
color represents the YFP fluorescence of cGi500. Scale bar 10 µm. (C) cGMP measurement in CGNs
upon stimulation with DEA/NO (100 nM), ANP (100 nM), and CNP (100 nM). Green, cyan, and orange
traces represent CFP/YFP ratio, CFP emission, and YFP emission, respectively. Scale bars represent
the change in fluorescence of the single fluorophores CFP or YFP (∆F/F) or their ratio (CFP/YFP;
∆R/R reflecting [cGMP]). The signals are from a single cell representative of the data set (n = 57 cells
measured on six coverslips obtained from three independent cultures). (D) Increasing concentrations
of DEA/NO were applied to CGNs to establish a concentration-response curve. The EC50 of CGNs
for DEA/NO was ≈32 nM. Data are presented as mean ± SEM (n = 12 cells per data point; cells from
one culture were measured on one coverslip). (E) Acute cerebellar slice isolated from a 7-week-old
R26-CAG-cGi500(L1) mouse. The green color represents the YFP fluorescence of cGi500. Scale bar is
20 µm. (F) cGMP measurement in the granule cell layer of a cerebellar slice upon stimulation with ANP
(250 nM), CNP (250 nM), and DEA/NO (5 µM). Green, cyan, and orange traces represent CFP/YFP
ratio, CFP emission, and YFP emission, respectively. Scale bars represent the change in fluorescence
of the single fluorophores CFP or YFP (∆F/F) or their ratio (CFP/YFP; ∆R/R reflecting [cGMP]).
The signals are from a single region of interest representative of the data set (n = 3 acute cerebellar slices
analyzed in three independent experiments). (G) Representative picture of a CGN primary culture
stained for βIII-tubulin (neuronal marker, green) and nuclei with Hoechst dye (blue); an overlay of
both channels is also shown (Merge). Scale bar is 10 µm.
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2. Results
2.1. cGMP Imaging in CGNs and Acute Cerebellar Slices Reveals a NO-Induced cGMP Response
Primary CGN cultures were prepared from 7-day-old R26-CAG-cGi500(L1) mice [27],
which express the cGi500 sensor ubiquitously. As expected, CGNs showed a strong expression
of the cGMP sensor protein (Figure 1B, green fluorescence). It is important to note that the green
fluorescence shown in Figure 1B shows the YFP emission of the sensor and not the cGMP concentration,
which is reflected by the CFP/YFP emission ratio. To determine which substances can induce a
reliable elevation of cGMP in CGNs, the cells were exposed to ANP (100 nM), CNP (100 nM), or the
NO-releasing compound diethylamine NONOate (DEA/NO) (100 nM) during real-time imaging
under continuous flow. As documented in Figure 1C, application of DEA/NO induced a robust
cGMP elevation as indicated by a simultaneous increase in CFP emission (cyan trace) and decrease in
YFP emission (orange trace), resulting in an increased CFP/YFP ratio (green trace). Application of
ANP or CNP did not result in a cGMP increase. To determine the sensitivity of the cGMP response
of CGNs to DEA/NO, a concentration-response experiment was performed, revealing an EC50 of
≈32 nM (Figure 1D). cGMP was also visualized in freshly prepared cerebellar slices isolated from
R26-CAG-cGi500(L1) mice (Figure 1E). Cerebellar slices were exposed to ANP (250 nM), CNP (250 nM),
and DEA/NO (5 µM) during real-time imaging under continuous flow. As expected, the application of
DEA/NO, but not ANP or CNP, resulted in elevated cGMP in the granule cell layer of the cerebellum
(Figure 1F, green trace). The failure to detect ANP- or CNP-induced cGMP increases (Figure 1C,F)
could have been related to technical issues, such as an inability of the cytosolic cGi500 sensor to detect
presumably membrane-associated cGMP pools that are generated in response to natriuretic peptides.
However, this possibility is highly unlikely, because the cytosolic cGi500 sensor has been successfully
used to detect ANP- and CNP-induced cGMP signals in various other cell types including smooth
muscle cells [27] and dorsal root ganglion neurons [29].
To confirm that our cultured cells were indeed neurons, cells were stained for the neuronal marker
βIII-tubulin (Figure 1G). Over 95% of cells (detected by nuclear staining with Hoechst dye) were
positive for βIII-tubulin indicating a nearly pure neuronal cell culture. The cultured cells had the
typical morphology and small size (diameter ≈ 5–10 µm) of CGNs (Figure 1B), but we cannot formally
exclude that our cerebellar cultures also contained a small number of Golgi and/or stellate neurons.
Together, these data indicated that NO was able to reliably elevate cGMP in CGNs in the primary
culture as well as in acute cerebellar slices.
2.2. Simultaneous Imaging Implicates the NO-cGMP Pathway in Potentiation of Glutamate-Induced Ca2+
Transients in CGNs
To evaluate a potential crosstalk of NO-cGMP and Ca2+ signaling, CGNs from
R26-CAG-cGi500(L1) mice were loaded with the fluorescent Ca2+ indicator Fura-2, and then cGMP
and Ca2+ were monitored simultaneously (Figure 2). Experiments were conducted under continuous
flow to allow for the addition of different substances to investigate their influence on cGMP and Ca2+
signaling in real time. As shown in Figure 2A, brief repetitive stimulation of CGNs with glutamate
(100 µM) induced reliable Ca2+ transients (black trace), but no changes of the intracellular cGMP
concentration (green trace). On the other hand, DEA/NO (100 nM) increased the cGMP level but
had no effect on the intracellular Ca2+ concentration ([Ca2+]i) under baseline conditions (Figure 2B).
However, when glutamate was applied in the presence of DEA/NO and an elevated cGMP level,
glutamate-induced Ca2+ transients were significantly potentiated when compared to control Ca2+
transients in the absence of DEA/NO (Figure 2A–C). To evaluate the effect of NO-induced cGMP on
the glutamate-induced rise in the Ca2+ concentration, the peak height of the second Ca2+ transient
(in the presence of Tyrode buffer or DEA/NO) was divided by the peak height of the first Ca2+
transient (in the absence of DEA/NO). Stimulation of CGNs with glutamate during superfusion
with DEA/NO resulted in a significantly augmented [Ca2+]i compared to control cells that were
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stimulated with glutamate and superfused with Tyrode buffer, with a second peak to first peak height
ratio of ≈1.2 versus ≈0.7 (Figure 2C; p < 0.001). These data depicted a NO-induced augmentation of
glutamate-induced Ca2+ transients in primary mouse CGNs.
NO could have influenced [Ca2+]i via a cGMP-dependent or -independent mechanism.
To determine the importance of cGMP in the observed augmented [Ca2+]i, CGN cultures were prepared
from cGMP sensor mice, which lacked the β1 subunit of NO-GC (NO-GC KO) [30] and, therefore,
expressed no functional NO-GC. These CGNs showed normal glutamate-induced Ca2+ transients
(Figure 2D, black trace, and Figure 2F, Tyrode). As expected, NO-GC KO CGNs showed no increase in
the cGMP concentration upon addition of DEA/NO (100 nM) (Figure 2E, green trace), confirming the
absence of functional NO-GC in these cells. In contrast to wild-type CGNs (Figure 2A–C), NO-GC
KO cells showed similar glutamate-induced Ca2+ transients in the absence and presence of DEA/NO
(Figure 2D–F). These results strongly supported the notion that NO potentiation of [Ca2+]i in CGNs is
mediated by activation of NO-GC and generation of cGMP.
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were exposed to glutamate alone and then to DEA/NO, followed by a second stimulation with 
glutamate in the presence of DEA/NO. (C) Quantification of the results obtained under conditions 
shown in (A,B). Depicted is the ratio of the [Ca2+]i peak heights (second over first peak) of individual 
cells. Data are presented as mean ± SEM; *** p < 0.001 (n = 17 cells for Tyrode, n = 25 cells for DEA/NO, 
measured on six coverslips obtained from three independent cultures). (D–F) Imaging of cGi500-
expressing CGNs with a genetic deletion of NO-GC (NO-GC KO). (D) Brief repetitive stimulation 
with glutamate under control conditions. (E) CGNs were exposed to glutamate alone and then to 
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Quantification of the results obtained under conditions shown in (D,E). Depicted is the ratio of the 
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analogue 8-Br-cGMP (100 µM) or 8-pCPT-cGMP (100 µM). In the presence of 8-Br-cGMP or 8-pCPT-
cGMP, glutamate-induced Ca2+ transients were significantly augmented compared to controls 
without cGMP analogues (Figure 3A, p < 0.05; Figure 3B, p < 0.01). In the experiments with 8-Br-
cGMP, we noted that the peak height ratio of the second over the first Ca2+ transient under control 
conditions (Tyrode) was ≈1.6 (Figure 3A). This value was higher than the control ratios obtained in 
the other experiments, which were ≈0.8–1.0 (Figures 2C,F and 3B). The variability of control transients 
might be related to different growth states of different CGN cultures. However, it is important to note 
Figure 2. Simult neous measu ment of cGMP and Ca2+ evealed cGMP–Ca2+ crosstalk in CGNs.
Traces depict cGMP (green) visualized with the cGi500 sensor, and [Ca2+]i (black) visualized with Fura-2.
CGNs were expose to glut mate (100 µM) (for 10 , represented by vertical arrows) to elevate [Ca2+]i,
and to DEA/NO (100 nM) (represented by horizontal bars) to increase the cGMP concentration. Tyrode
buffer was used as a control in the absence of DEA/NO. Traces depict representative measurements
of individual cells. Scale bars represent the change in flu rophore ratio (∆R/R reflecting [cGMP]
or [Ca2+]i). (A–C) Imaging of cGi500-expressing CGNs with NO-GC wild type alleles (wild type).
(A) Brief repetitive stimulation with glutamate under control conditions. (B) CGNs were exposed to
glutamate alone and then to DEA/NO, followed by a second stimulation with glutamate in the presence
of DEA/NO. (C) Quantification of the results obtained under conditions shown in (A,B). Depicted is
the ratio of the [Ca2+]i peak heights (second over first pe k) of individual cells. Data are presented
as mean ± SEM; *** p < 0.001 (n = 17 cells for Tyrode, n = 25 cells for DEA/NO, measured on six
coverslips obtai ed from three independent cultures). (D–F) Imaging of cGi500-expres ing CGNs with
a genetic deletion of NO-GC (NO-GC KO). (D) Brief repetitive stimulation with glutamate under control
conditions. (E) CGNs were exposed to glutamate alo e nd then to DEA/NO followed by a second
stimulation with glutamate in the presence of DEA/NO. (F) Quantification of the results obtained
under conditions shown in (D,E). Depicted is the ratio of the [Ca2+]i pe k heights (second over first
peak) of individual cells. Data are presented as mean± SEM; n.s., not significant (n = 90 cells for Tyrode,
n = 60 cells for DEA/NO, measured on twelve coverslips obtained from two independent cultures).
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2.3. Use of cGMP Analogues Confirms cGMP-Dependent Increase of Glutamate-Induced Ca2+ Transients
To further test the importance of cGMP in augmented glutamate-induced Ca2+ signals, CGNs
were stimulated with glutamate (100 µM) during superfusion with the membrane-permeable
cGMP analogue 8-Br-cGMP (100 µM) or 8-pCPT-cGMP (100 µM). In the presence of 8-Br-cGMP
or 8-pCPT-cGMP, glutamate-induced Ca2+ transients were significantly augmented compared to
controls without cGMP analogues (Figure 3A, p < 0.05; Figure 3B, p < 0.01). In the experiments with
8-Br-cGMP, we noted that the peak height ratio of the second over the first Ca2+ transient under
control conditions (Tyrode) was ≈1.6 (Figure 3A). This value was higher than the control ratios
obtained in the other experiments, which were ≈0.8–1.0 (Figure 2C,F and Figure 3B). The variability
of control transients might be related to different growth states of different CGN cultures. However,
it is important to note that control cells (treated with Tyrode) and experimental cells (treated with
DEA/NO or cGMP analogues) were always measured side-by-side with the same batch of cells.
Therefore, the potential variability in the control ratio between different CGN cultures should not
have been a major confounding factor in these experiments. The results with cGMP analogues further
supported a cGMP–Ca2+ crosstalk in CGNs, which could be mediated via cGKs, CNG channels,
or other cGMP effector proteins.
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Both antibodies were validated with respective knockout tissues to confirm their specificity. While 
the cGKI protein was readily detected in lysates from colon and cerebellum isolated from wild type 
mice, it was not detected in primary CGNs (Figure 4A). The cGKII protein was detected in lysates 
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Figure 3. The addition of c MP analogues confirmed cGMP–Ca2+ crosstalk in GNs. (A) Quantification
of glutamate (100 µM, 10 s)-induced elevation of [Ca2+]i in the absence of cGMP analogue (Tyrode) or
after pre-incubation of cells with 100 µM 8-Br-cGMP for 5.5 min. Data are depicted as the ratio of the
[Ca2+]i peak heights of individual cells (second over first peak, where the second peak was induced
by glutamate in the presence of Tyrode or 8-Br-cGMP) and presented as mean ± SEM; * p < 0.05
(n = 15 cells for Tyrode, n = 34 cells for 8-Br-cGMP, measured on seven coverslips obtained from three
independent cultures). (B) Quantification of glutamate (100 µM, 10 s)-induced elevation of [Ca2+]i in
the absence of cGMP analogue (Tyrode) or after pre-incubation of cells with 100 µM 8-pCPT-cGMP for
5.5 min. Data are depicted as the ratio of the [Ca2+]i peak heights of individual cells (second over first
peak, where the second peak was i duced by glutamate in the presence of Tyrode or 8- CPT-cGMP)
and presented as mean ± SEM; ** p < 0.01 (n = 29 cells for Tyrode, n = 22 cells for 8-pCPT-cGMP,
measured on six coverslips obtained from two independent cultures).
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2.4. Western Blot Analysis Does Not Detect cGKI or cGKII Expression in CGNs
To determine if cGKs could be downstream targets of cGMP, lysates from our CGN primary
cultures were analyzed via Western blot with highly specific cGKI and cGKII antibodies (Figure 4).
Both antibodies were validated with respective knockout tissues to confirm their specificity. While
the cGKI protein was readily detected in lysates from colon and cerebellum isolated from wild type
mice, it was not detected in primary CGNs (Figure 4A). The cGKII protein was detected in lysates
from jejunum of wild type mice, as well as in cerebellum isolated from wild type or cGKI knockout
mice, but it was not detected in the our CGN lysates (Figure 4B).
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second peak was induced by glutamate in the presence of Tyrode or 8-Br-cGMP) and presented as 
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2.4. Western Blot Analysis Does Not Detect cGKI or cGKII Expression in CGNs 
To determine if cGKs could be downstream targets of cGMP, lysates from our CGN primary 
cultures were analyzed via Western blot with highly specific cGKI and cGKII antibodies (Figure 4). 
Both antibodies were validated with respective knockout tissues to confirm their specificity. While 
the cGKI protein was readily detected in lysates from colon and cerebellum isolated from wild type 
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Figure 4. Western blot analysis failed to detect cGKI or cGKII expression in primary CGNs. (A) Lysates
prepared from CGN cultures grown for 5 days in vitro (10 µg), colon (10 µg), and cerebellum of a wild
type mouse (wt) (10 µg), as well as cerebellum of a cGKI knockout mouse (cGKI KO) (10 µg) were
stained with a highly specific cGKI antibody. GAPDH was used as a loading control. Representative
data from three independent CGN primary cultures are shown. (B) Lysates prepared from CGN
cultures grown for 5 days in vitro (30 µg), jejunum (20 µg), and cerebellum of a wild type mouse (wt)
(70 µg), as well as cerebellum of a cGKI knockout mouse (cGKI KO) (70 µg) and of a cGKII knockout
mouse (cGKII KO) (70 µg) were stained with a highly specific cGKII antibody. β-actin was used
as a loading control. Representative data from two independent CGN primary cultures are shown.
Expected molecular weights of respective proteins are indicated on the right. CGN cultures were
established from 7-day-old wild type mice (wt P7) and extracts of the cerebellum and internal organs
were prepared from 8- to 25-week-old mice.
2.5. Real-Time cGMP Imaging in CGNs Reveals cGMP Degradation via Zaprinast-Sensitive PDEs
To evaluate which PDE(s) degrade cGMP in murine CGNs, the cells were exposed to various
PDE inhibitors. CGNs from cGMP sensor mice were first superfused with DEA/NO (50 nM) alone
(Figure 5A, first peak), and then with the general PDE inhibitor IBMX (100 µM) followed by DEA/NO
(50 nM) in the presence of IBMX (Figure 5A, second peak) and a final application of DEA/NO (50 nM)
alone (Figure 5A, third peak). IBMX alone had no influence on the basal cGMP level in cultured CGNs,
however, it strongly potentiated the cGMP increase elicited by DEA/NO compared to DEA/NO
alone (Figure 5A). To identify the PDEs that play a role in cGMP degradation in CGNs, specific PDE
inhibitors [13] were applied in the same manner as shown for IBMX in Figure 5A. These PDE inhibitors
were Vinpocetine (5 µM) for PDE1, Bay 60-7550 (10 nM) for PDE2, EHNA (10 µM) for PDE2, Milrinone
(10 µM) for PDE3, Sildenafil (20 µM) for PDE5, and Zaprinast (20 µM) for PDE5, 6, 9, 10, and 11.
These measurements (Figure 5B) revealed a weak but significant effect of Sildenafil (p < 0.05) and
a strong effect of Zaprinast (p < 0.05). The other tested PDE inhibitors did not show statistically
significant effects on NO-induced cGMP elevation. These data implicated PDE5, 6, 9, 10, and 11 as
possible cGMP-degrading PDEs in murine CGNs.
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Figure 5. Real-time cGMP imaging in CGNs reveals degradation of cGMP by Zaprinast-sensitive PDEs.
(A) cGi500-expressing CGNs isolated from R26-CAG-cGi500(L1) mice were stimulated three times with
DEA/NO (50 nM), first with DEA/NO alone, then in the presence of IBMX (100 µM), and finally again
with DEA/NO alone. The bar graph shows the statistical evaluation of DEA/NO-induced cGMP peak
areas before (first peak), during (second peak), and after (third peak) incubation with IBMX. Peak areas
were normalized to the first peak of each experiment. Data are presented as mean ± SEM; * p < 0.05
first versus second peak (n = 6 cells measured on three coverslips obtained from three CGN cultures).
(B) As described for (A), CGNs were superfused with DEA/NO (50 nM) in the absence and presence
of indicated PDE inhibitors. The following PDE inhibitors were tested: 5 µM Vinpocetine (Vin); 10 nM
Bay 60-7550 (Bay); 10 µM EHNA; 10 µM Milrinone (Mil); 20 µM Sildenafil (Sil); 20 µM Zaprinast (Zap).
Data are presented as mean ± SEM; * p < 0.05 first versus second peak (n = 6–12 cells per condition;
cells were measured on two coverslips obtained from two CGN cultures).
3. Discussion
In this study, we have investigated NO-cGMP signal transduction in CGNs by real-time imaging
of cGMP and Ca2+. cGMP imaging in acute cerebellar slices and individual CGNs in primary culture
revealed that NO, but not ANP and CNP, was able to induce an increase in cGMP, which indicated that
the cGMP synthesizing enzyme NO-GC was present, while particulate guanylyl cyclases stimulated
by ANP or CNP were not. Importantly, we have identified a NO-cGMP-dependent augmentation
of glutamate-induced Ca2+ transients in CGNs. These results complement other research that has
demonstrated NO-cGMP signaling in CGNs [21,31]. A recent report used cGMP imaging in acute brain
slices of cGMP sensor mice to demonstrate NO-induced cGMP elevations in the cerebellum, striatum,
and hippocampus [32]. In contrast to the present study, which was conducted with transgenic mice
expressing the cGMP sensor ubiquitously, Peters and colleagues used a neuron-specific cGMP sensor
mouse model. In this model, they also found robust NO-induced cGMP signals in the granule cell
layer of the cerebellum [32], thus, providing further support for the presence of a NO-cGMP signalling
cascade in CGNs in vivo.
With the knowledge that NO was able to induce a robust cGMP response in CGNs, we investigated
a potential crosstalk between the NO-cGMP pathway and glutamate-induced Ca2+ signaling via
simultaneous imaging of cGMP and Ca2+ in individual CGNs in primary cultures. Brief repetitive
stimulation of our CGNs with glutamate evoked robust Ca2+ transients. The glutamate-induced
Ca2+ elevations were likely mediated by the NMDA receptor [33], but we could not exclude other
types of glutamate receptors as sources of Ca2+ entry. It has been reported that upon activation of
Ca2+-permeable NMDA-type glutamate receptors in the brain, NO synthase is activated and NO
synthesized, which then activates NO-GC and elevates intracellular cGMP levels [25,26]. Other
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work has proposed that Ca2+ entry might decrease NO donor-induced cGMP levels in CGNs via
activation of Ca2+/calmodulin-stimulated PDE1 [34]. However, at no time during the addition of
glutamate, in the absence or presence of the NO donor DEA/NO, did we observe a glutamate-/Ca2+
entry-triggered change of the cGMP concentration in our CGNs (Figure 2A,B). This could be a result
of the short duration that CGNs were exposed to glutamate (10 s), compared to experiments where
NMDA receptors were stimulated for minutes [25,26]. Moreover, we did not detect functional PDE1 in
our CGNs (Figure 5B).
Interestingly, during exposure of CGNs to DEA/NO, a significant augmentation of glutamate-
induced Ca2+ transients was observed indicating that NO potentiates Ca2+ entry. Given that NO can
also produce cGMP-independent effects [1], it was important to determine if the observed NO-induced
[Ca2+]i augmentation was indeed cGMP-dependent. To investigate this, we analyzed CGNs from
knockout mice lacking functional NO-GC. In line with our hypothesis, exposure of NO-GC KO CGNs to
NO did not produce cGMP and did not augment glutamate-induced Ca2+ transients. To provide further
evidence for the importance of cGMP in the potentiation of glutamate-induced elevation of [Ca2+]i,
we exposed CGNs to the membrane-permeable cGMP analogues 8-Br-cGMP and 8-pCPT-cGMP.
Indeed, both cGMP analogues were effective and enhanced glutamate-induced elevation of [Ca2+]i.
These results support the notion that NO potentiates glutamate-induced Ca2+ transients in murine
CGNs via activation of NO-GC and synthesis of cGMP. Interestingly, a recent study reported that the
slow alcohol-induced increase of [Ca2+]i in CGNs was suppressed by pre-incubation of the cells with
8-Br-cGMP [35]. Thus, it appears that activation of cGMP signaling in CGNs can both increase and
decrease [Ca2+]i depending on the type of Ca2+ signal.
What could be the mechanism downstream of cGMP that augments glutamate-induced Ca2+
transients in CGNs? Although 8-Br-cGMP and 8-pCPT-cGMP are commonly used to activate
cGKs, it is important to note that these cGMP analogues also bind to and modulate the activity
of other cGMP downstream targets such as PDEs and CNG channels [36,37]. Indeed, previous
work has reported a slow increase in resting [Ca2+]i in Fura-2 loaded rat CGNs upon the addition
of 8-Br-cGMP, suggesting the presence of functional CNG channels [38]. However, under our
experimental conditions, resting [Ca2+]i was not affected by NO-induced endogenous cGMP (Figure 2B)
or two cGMP analogues, 8-Br-cGMP and 8-pCPT-cGMP (data not shown). Thus, it is unlikely that
the augmentation of glutamate-induced Ca2+ transients by these agents, as observed in our study,
was related to the activation of CNG channels. Rat CGNs also express hyperpolarization-activated
cyclic nucleotide-gated channels [39]. However, because these ion channels are principally activated by
cAMP and not cGMP, it is unlikely that they were directly involved in the effects of our test compounds.
Future studies are required to identify the cGMP effector mechanism behind the potentiation of
glutamate-induced Ca2+ transients in CGNs by NO-cGMP signaling.
Previous work with genetically-modified mice has demonstrated important roles of cGKI in the
brain, from modulation of synaptic plasticity in hippocampal neurons [40] and cerebellar Purkinje
cells [20] to the regulation of sleep-wake activity [41]. Interestingly, cGKI also mediates cGMP–Ca2+
crosstalk in vascular smooth muscle cells. However, activation of cGKI in these cells typically results
in suppression of agonist-evoked increases of [Ca2+]i [42–44], suggesting that cGKI is not the effector
of the NO-cGMP-mediated increase of [Ca2+]i observed in CGNs. Indeed, Western blot analysis did
not detect cGKI or cGKII protein expression in our primary mouse CGNs. These findings contrast with
previous studies of the Torres lab. These authors detected cGKI mRNA and protein and cGKII mRNA in
CGNs via qPCR and Western blotting, and they reported important roles of cGKI and cGKII in synaptic
vesicle recycling in CGNs [21,31,45,46]. The discrepancy in expression data could be explained by
methodological differences. First, we did not analyze mRNA levels but used highly specific antibodies,
which we validated with knockout tissues, to detect cGKI and cGKII proteins. Torres and colleagues
used a different cGKI antibody with presumably different specificity and sensitivity for Western
blotting, and they did not analyze cGKII expression at the protein level. It is interesting to note that
while we were not able to detect cGKI and cGKII in our CGN lysates, both proteins were readily
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detected in extracts of whole cerebellum. This suggests that cell types other than CGNs express
cGKI and/or cGKII in the cerebellum. Indeed, immunohistochemical staining of cerebellar sections
showed strong expression of cGKI in cerebral vessels and Purkinje neurons, but no evidence for
its expression in CGNs [10,20]. Another reason for discrepant results regarding the expression and
functional relevance of cGKs and CNG channels could be that CGNs develop a differential expression
of these cGMP pathway components upon culturing over time [21,38]. Moreover, most previous
studies of NO-cGMP signaling in CGNs were done in rat cells, while we used CGNs from mice.
Thus, differences in antibody selectivity and sensitivity, culture conditions/times, as well as species
differences might account for differences in protein expression observed in our studies and those by
Torres and co-workers. Our studies, as well as those by Torres et al., were performed with CGNs
isolated from young (P7) mice or rats. Since cGMP signaling in the brain may dramatically change
with aging [47], we should be careful with extrapolating our findings to CGNs in the adult cerebellum.
cGMP degradation occurs via PDEs and many of the eleven PDE families have been reported in
the CNS [13,48,49]. To our knowledge, the PDEs involved in cGMP degradation in CGNs have not
been systematically characterized. With our FRET-based cGi500 sensor, it was possible to investigate
the role of PDEs in cGMP degradation in individual living CGNs in real time (Figure 5B). NO-induced
cGMP levels were not affected by inhibitors of PDE1, 2, and 3, while they were strongly potentiated by
Zaprinast, which inhibits PDE5, 6, 9, 10, and 11. Addition of the PDE5 inhibitor Sildenafil resulted in a
small increase in cGMP (Figure 5B). Our findings are consistent with the reported expression of PDE9
in rat CGNs [50] and of PDE9, but not PDE2, in CGNs of the human brain [51]. Previous research
performed in rodents and humans has suggested that PDE9, 10, and 11 play a role in neurological
diseases, such as PDE9 in bipolar affective disorder [52], PDE10 in social interaction, schizophrenia,
and bipolar disorder [53–55], and PDE11 in major depression [56]. However, neither PDE6 nor PDE11
are expressed in the cerebellum [13,49,57]. PDE9 appears to be localized to the membrane and nuclear
fractions of cerebellar tissue [58]. In heart muscle, PDE9 specifically regulates cGMP pools that are
generated by membrane-associated particulate guanylyl cyclases rather than cytosolic NO-GC [59].
Thus, we propose that PDE5 and PDE10 are the most likely candidates that degrade NO-induced
cGMP in murine CGNs.
Several imaging-based studies have identified important functions of cGMP, cAMP, and Ca2+ in
neuronal cells and, interestingly, complex relationships between the spatiotemporal dynamics of these
signaling molecules. For instance, reciprocal regulation of cAMP and cGMP modulates axon/dendrite
formation in hippocampal neurons [60]. In this study, FRET imaging showed that alterations of
the amount of cAMP resulted in opposite changes in the amount of cGMP, and vice versa, through
the activation of PDEs and protein kinases. Another study showed that the NO-cGMP pathway
inhibits transient cAMP signals through the activation of PDE2 in striatal neurons [15]. Recently,
an interplay among cGMP, cAMP, and Ca2+ has been described in olfactory sensory neurons [61] and
dorsal root ganglion neurons [62,63], as well as an association of this signaling crosstalk with axonal
pathfinding and neurotransmitter release. Thus, it is tempting to speculate that the cGMP–Ca2+
crosstalk in CGNs identified in the present study also involves cAMP. In the future, it will be
interesting to monitor cGMP/cAMP and cAMP/Ca2+ simultaneously in individual CGNs with the use
of spectrally compatible fluorescent indicators. With these experiments, one could test the hypothesis
that NO-cGMP signaling modulates the cAMP level, presumably via regulation of cAMP-degrading
PDEs, and that cAMP in turn regulates glutamate-induced Ca2+ transients in CGNs.
In sum, real-time imaging of cGMP and Ca2+ combined with expression analysis of cGKI and
cGKII indicates the presence of a cGK-independent NO-cGMP signaling cascade that potentiates
glutamate-induced Ca2+ transients in murine CGNs, and a Zaprinast-sensitive degradation of cGMP
in these cells. These findings deepen our mechanistic understanding of cGMP signaling in the CNS.
The cGMP–Ca2+ crosstalk reported here likely influences neurotransmitter-stimulated functions of
CGNs and perhaps other neuronal cell types and might be targeted by cGMP-modulating medications
to treat neurological disorders.
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4. Materials and Methods
4.1. Mice
All animal procedures were performed in compliance with the humane care and use of
laboratory animals and approved by the local authority (Regierungspräsidium Tübingen, IB 1/15,
21 August 2015). Mice were housed at 22 ◦C and 50–60% humidity in a 12 h light/12 h dark
cycle with access to standard rodent chow and tap water. The following mouse lines were
used: R26-CAG-cGi500(L1) [27], NO-GC KO [30], and R26-CAG-cGi500(L1);NO-GC KO cross mice.
Genotyping of the animals was performed by PCR analysis of ear puncture DNA using the following
primers: for detection of the R26-CAG-cGi500(L1) allele, BB01 (CTCTGCTGCCTCCTGGCTTCT),
BB02 (CGAGGCGGATCACAAGCAATA) and BB03 (TCAATGGGCGGGGGTCGTT), which amplify
a 330-bp fragment of the wild type allele (BB01 and BB02) and a 250-bp fragment of the
transgene (BB01 and BB03); for NO-GC KO mice, BB19 (AAGATGCTGAAGGGAAGGATGC), BB20
(CAGCCCAAAGAAACAAGAAGAAAG) and BB21 (GATGTGGGATTGTTTCTGAGGA), which
amplify a 680-bp fragment of the wild type allele (BB19 and BB20) and a 830-bp fragment of the
knockout allele (BB19 and BB21).
4.2. Drugs
The following drugs were used: ANP and CNP (Tocris, Bristol, UK), DEA/NO (Axxora,
Ann Arbor, MI, USA), glutamate (Sigma, St. Louis, MO, USA), IBMX (Sigma), Vinpocetine
(Cayman, Ann Arbor, MI, USA), Bay 60-7550 (Cayman), EHNA (Axxora), Milrinone (Sigma),
Sildenafil (Cayman), Zaprinast (Santa Cruz, Dallas, TX, USA), 8-Br-cGMP (Biolog, Bremen, Germany),
and 8-pCPT-cGMP (Biolog).
4.3. Cell Culture
To establish primary cultures of cerebellar granule neurons (CGNs) from mice, the following
solutions and “tubes” were prepared: 10× Krebs buffer (1.24 M NaCl, 54 mM KCl, 5 mM NaH2PO4,
pH 7.4); 0.3% bovine serum albumin (BSA, Roth, Karsruhe, Germany) solution in 1× Krebs buffer,
14.3 mM D-glucose, 2.5 mM MgSO4, sterilized by filtration; “tube 1” contained 30 mL 0.3% BSA
solution; “tube 2” contained 30 mL 0.3% BSA solution and 300 µL trypsin solution (2.5× trypsin-EDTA
(Thermo Scientific, Waltham, MA, USA) in PBS), added shortly before use; “tube 3” contained 7.8 mg
trypsin inhibitor (Life Technologies, Carlsbad, CA, USA) in 15 mL 0.3% BSA solution, 3.1 mM MgSO4,
and 0.1 mg/mL DNase (Roche, Basel, Switzerland), added shortly before use); in “tube 4”, 17 mL 0.3%
BSA solution weas mixed with 8 mL solution from “tube 3” and then 10 mL was discarded, so that
15 mL remained in “tube 4”; “tube 5” contained 12.5 mL 0.3% BSA solution, 2.5 mM MgSO4, and 0.1 mM
CaCl2. Two to five cerebella from 7-day-old mice were isolated and the surrounding meninges were
removed in 0.3% BSA solution. Then, the cerebella were homogenized in 2 mL 0.3% BSA solution
with a pipette, transferred into “tube 1” and centrifuged at 170× g for 5 min at room temperature.
The supernatant was removed, and the pellet was resuspended in the solution from “tube 2” and
incubated for 15 min at 37 ◦C with gentle shaking every 5 min. Then, the suspension was transferred
into “tube 4”, mixed, and centrifuged at 170× g for 5 min at room temperature. The supernatant was
removed, and the cell pellet was resuspended in the solution from “tube 3” by pipetting 10 times
with a Pasteur pipette. Then, the suspension was transferred into “tube 5”, mixed, passed through
a netwell mesh (70 µm), and centrifuged at 170× g for 5 min at room temperature. The pellet was
resuspended in CGN medium (Minimal Essential Medium (Life Technologies) containing 22 mM KCl,
2% B27 supplement (Thermo Scientific), 9% fetal bovine serum (Thermo Scientific), 0.3 mM glutamine
(Thermo Scientific), and 0.1 mM gentamicin (Thermo Scientific)) and plated on 24-well plates (100 k
cells per well, viability > 95% as determined by trypan blue staining). Wells were equipped with glass
coverslips, which had been coated overnight with poly-D-lysine (20 µg/mL, Thermo Scientific). CGNs
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were grown at 37 ◦C and 5% CO2, and after 24 h cytosine arabinoside (5 µM, Sigma) was added. Every
3 days, half of the medium was changed.
4.4. Imaging
FRET/cGMP and Ca2+ imaging of cultured CGNs was performed 5–7 days after plating using an
epifluorescence setup as described previously [27,29,64]. Briefly, the setup consisted of an inverted
Axiovert 200 microscope (Zeiss, Oberkochen, Germany) equipped with a NeoFluar40x/1.30 oil
objective, a light source with excitation filter switching device (Oligochrome, TILL Photonics GmbH,
Graefelfing, Germany), a Dual-View beam splitter (Photometrics) with 516 nm dichroic mirror and
emission filters for CFP (480/30 nm) and YFP (535/40 nm), and a charge-coupled device camera
(Retiga 2000R; QImaging, Surrey, BC, Canada).
cGMP imaging was performed with CGNs from R26-CAG-cGi500(L1) mice expressing the cGi500
sensor. For simultaneous imaging of cGMP and Ca2+, coverslips with cGMP sensor cells were incubated
with 2.5 µM Fura-2AM (Calbiochem, San Diego, CA, USA; 1 mM stock solution in DMSO) in Tyrode
buffer (140 mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 2.5 mM CaCl2, 5 mM D-glucose, 5 mM HEPES,
pH 7.4) for 35 min at 37 ◦C in the dark before measurement. Coverslips were mounted into a Warner
Instrument SA-20LZ superfusion imaging chamber (Harvard Bioscience, Holliston, MA, USA) and
superfused at 37 ◦C at a flow rate of 1 mL/min with Tyrode buffer or Tyrode buffer supplemented with
drugs. Test compounds were applied via Pharmacia IV-7 injection valves (GE Healthcare, Chicago,
IL, USA) with either 7.0, 2.0, or 0.16 mL sample loops. Cells were imaged at 40× magnification
and 4 × 4 binning. Signals were recorded at a frequency of 5 Hz or 1 Hz for cGMP imaging alone
or simultaneous cGMP/Ca2+ imaging, respectively. For Fura-2-based Ca2+-imaging, fluorescence
was excited at 340/26 nm and 387/11 nm (15% lamp intensity each) and emission was recorded in
the 535/40 nm channel (65 ms and 20 ms exposure time with the respective excitation wavelength).
For cGMP imaging with cGi500, excitation was performed at 445/20 nm (45% lamp intensity) and
emission recorded simultaneously at 480/30 nm and 535/40 nm (40 ms exposure).
Acute brain slices were prepared with a vibratome and imaged with a spinning disk microscope
essentially as described in an accompanying study [32]. The setup consisted of an upright Examiner.Z1
microscope (Zeiss, Oberkochen, Germany), a Yokogawa CSU-X1 spinning disk confocal scanner, three
diode lasers (445 nm, 488 nm and 561 nm), three water immersion objectives (W N-ACHROMAT
10x/0.3, W Plan-APOCHROMAT 20x/1.0 DIC (UV) VIS-IR, W Plan-APOCHROMAT 40x/1.0 DIC
VIS-IR; all from Zeiss) and one air objective (EC Plan-NEOFLUAR 2.5x/0.085; Zeiss). For FRET-based
cGMP imaging, the donor fluorophore CFP was excited with the 445 nm laser, and a Dual-View beam
splitter (Photometrics) with 505 nm dichroic mirror, and 470/24 nm and 535/30 nm emission filters was
used for simultaneous acquisition of CFP and YFP. Signals were recorded with an electron-multiplying
charged-coupled device (EM-CCD) camera (QuantEM 512SC, Photometrics) at a frame rate of 0.2 Hz
and an exposure time of 300 ms. The system was controlled by VisiView software (Visitron Systems).
A CoolLED pE-2 LED system was used for epifluorescence illumination at 400 nm, 450 nm, 500 nm,
and 561 nm. During real-time imaging, the tissue was continuously superfused with carbogen-gassed
Ringer buffer (126 mM NaCl, 2.5 mM KCl, 1 mM MgCl2, 1 mM CaCl2, 1.25 mM NaH2PO4, 26 mM
NaHCO3, 20 mM D-glucose) or Ringer buffer containing drugs of interest at a flow rate of 1 mL/min
at 37 ◦C. A custom-built superfusion system was used consisting of a FPLC pump (Pharmacia P-500,
GE Healthcare), FPLC injection valves (Pharmacia V-7, GE Healthcare), a magnetic platform (Warner
instruments, Holliston, MA, USA), a superfusion chamber (RC-26, Warner Instruments), a Slice
Hold-Down (SHD-26H/10, Warner Instruments), and a sample loop (2 mL). To remove the buffer from
the system, a vacuum pump with adjustable vacuum (Laboport N86, KNF Neuberger, Freiburg im
Breisgau, Germany) was connected to the system [27,64].
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4.5. PDE Inhibitor Experiments
cGMP measurements with various PDE inhibitors were performed on the same microscopy setup
as described in 4.4. Primary CGNs were first stimulated for 2 min with DEA/NO (50 nM) alone and
then superfused for 5 min with PDE inhibitor followed by 2 min with DEA/NO (50 nM) and PDE
inhibitor in combination, and a final 2-min stimulation with DEA/NO (50 nM) alone. Subsequent
drug applications were performed after the preceding FRET signal had returned to baseline.
4.6. Protein Isolation and Western Blotting
CGNs on coverslips were treated with lysis buffer (0.67% SDS (w/v), 21 mM Tris/HCl (pH 8.3),
0.2 mM phenylmethylsulfonylfluoride, and one tablet of PhosSTOP™ phosphatase inhibitor cocktail
(Roche) per 10 mL). Protein concentrations of the cell lysates were measured with the Total Protein
Kit, Micro Lowry, Peterson’s modification (Sigma). Cell lysates were subjected to SDS-PAGE and
Western blot analysis on polyvinylidenefluoride membranes. Membranes were stained with the
following antibodies: rabbit polyclonal anti-cGKI (1:5000, [65]), rabbit monoclonal anti-GAPDH
(1:1000, Cell Signaling, Danvers, MA, USA, 2118), rabbit polyclonal anti-cGKII (1:100, [66]), or rabbit
polyclonal anti-β-actin (1:2000, Abcam, Cambridge, UK, 8227). Antibody binding was detected using
HRP-conjugated secondary antibodies (goat anti-rabbit IgG, 1:2000, Cell Signaling, 7074; or 1:7500,
Dianova, 111-035-003) and a chemiluminescent substrate (Advansta WesternBright ECL, Biozym;
or ClarityTM Western ECL Substrate, Bio-Rad Laboratories, Hercules, CA, USA). Signals were recorded
with a CCD camera (Alpha-Imager, Bio-Rad Laboratories; or ChemiDoc system, Bio-Rad Laboratories).
Further analysis was performed with Fiji (NIH, Bethesda, MD, USA) [67] or ImageLab software
(Bio-Rad Laboratories). Tissues were obtained from 8- to 25-week-old wild-type mice on a C57BL/6 or
mixed C57BL/6 × 129/Sv genetic background. Tissues were dissected in PBS and then homogenized
in lysis buffer using a FastPrep homogenizer (MP Biomedicals, Santa Ana, CA, USA) or ultra-turrax
(IKA, Staufen, Germany).
4.7. Immunostaining of Cells
CGNs on coverslips were washed two times with PBS and then treated with ice-cold immuno-fix
(3.7% formaldehyde in PBS) for 10 min. The cells were then washed three times with 0.5% BSA
(in PBS) and incubated in 5% Normal Goat Serum (in 0.5% BSA solution) for 1 h at room temperature.
The cells were then washed two times with 0.5% BSA and incubated with mouse monoclonal antibody
against βIII-tubulin (Cell Signaling, 4466, 1:1000 in 0.5% BSA with 0.01% Triton X-100) for 1 h at room
temperature. The cells were then washed two times with 0.5% BSA and then incubated with secondary
antibody conjugated with Alexa 488 (goat anti-mouse IgG, Cell Signaling, A-11029, 1:100 in 0.5%
BSA with 0.01% Triton X-100) and 1 µg/mL Hoechst 33258 (Sigma) for 30 min in the dark at room
temperature. The cells were then washed three times with 0.5% BSA and photographed with the
microscope setup described in Section 4.4.
4.8. Data Analysis and Statistics
Imaging data were analysed as previously described [27]. For image acquisition and online
analysis, VisiView (Visitron, Puchheim, Germany) was used, and for offline analysis Fiji software
(NIH) [67]. For further analysis, Microsoft Excel (Microsoft Corp., Redmond, WA, USA) and Origin
(OriginLab Corp., Northampton, MA, USA) were used. F480 signals (CFP emission at 480 nm, cyan
traces in respective graphs) and F535 signals (YFP emission at 535 nm, orange traces in respective
graphs) were background-corrected and used to calculate the F480/F535 ratio R (green traces in
respective graphs). F340 signals (intensity of emission at 535 nm after excitation at 340 nm) and
F387 signals (intensity of emission at 535 nm after excitation at 387 nm) were background-corrected
and used to calculate the F340/F387 ratio R (black traces in respective graphs). ∆F480/F480, ∆F535/F535,
∆F340/F340, ∆F387/F387 and corresponding ∆R/R traces were obtained by normalization to the baseline
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recorded for ≈3 min at the beginning of each experiment. For ∆R/R peak area and peak height
calculation, Peak Area/Height Analyzer of Origin was used. Peak borders were defined manually.
Statistical analysis was performed using Origin software. Statistical differences between more than
two groups were analyzed by one-way ANOVA followed by Bonferroni’s test. p values < 0.05 were
considered to be significant.
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ANP Atrial natriuretic peptide
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[Ca2+]i Intracellular Ca2+ concentration
CAG CMV immediate early enhancer, chicken β-actin, and rabbit β-globin
CFP Cyan fluorescent protein
cGi cGMP indicator
cGK cGMP-dependent protein kinase
cGMP Cyclic 3′ 5′ guanosine monophosphate
CGN Cerebellar granule neuron
CNG Cyclic nucleotide gated
CNP C-type natriuretic peptide
CNS Central nervous system
DEA/NO 2-(N,N-diethylamino)-diazenolate-2-oxide diethylammonium salt
FRET Förster/Fluorescence resonance energy transfer
IBMX 3-Isobutyl-1-methylxanthin
NMDA N-methyl-D-aspartate
NO Nitric oxide
NO-GC NO-sensitive guanylyl cyclase
NO-GC KO NO-sensitive guanylyl cyclase knockout
PBS Phosphate buffered saline
PDE Phosphodiesterase
YFP Yellow fluorescent protein
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